Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01366027 · ClinicalTrials.gov registry record
PRISM Registry: Pseudobulbar Affect Registry Series
A clinical trial, sponsored by Avanir Pharmaceuticals.
- Completed
- Registry status
- 5,290
- Enrollment target
NCT01366027 is a clinical trial that has completed, run by Avanir Pharmaceuticals. The registered enrollment target is 5,290 participants.
The verdict
NCT01366027 has completed, sponsored by Avanir Pharmaceuticals.
- COMPLETED
- Registry status
- 5,290 participants
- Enrollment target
Study Summary
PBA is a neurologic condition that is estimated to impact over a million patients and their families in the United States. PBA occurs secondary to an otherwise unrelated neurologic disease or injury, and manifests as involuntary, frequent, and disruptive outbursts of crying and/or laughing. Progress has been made in better understanding this debilitating condition, but much more needs to be done. That's why a new PBA patient registry, PRISM (Pseudobulbar Affect RegIstry Series), has been initiated. The goal of PRISM is to establish the prevalence and quality of life (QOL) impact of PBA in patients with underlying neurologic conditions including * Alzheimer's disease * Amyotrophic lateral sclerosis * Multiple sclerosis * Parkinson's disease * Stroke * Traumatic brain injury Because this is an observational registry, it doesn't require you to intervene with any specific treatment or procedure. Your participation allows the PRISM registry to collect and analyze data from your site and also compare it to national numbers captured in the PRISM registry about PBA across all of the major at-risk neurologic populations.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,290 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01366027
The ClinicalTrials.gov registry entry for NCT01366027 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avanir Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01366027 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01366027 about?
NCT01366027 is a clinical study titled "PRISM Registry: Pseudobulbar Affect Registry Series". PBA is a neurologic condition that is estimated to impact over a million patients and their families in the United States. PBA occurs secondary to an otherwise unrelated neurologic disease or injury, and manifests as involuntary, frequent, and disruptive outbursts of crying and/or laughing. Progress...
What is the current status of trial NCT01366027?
This trial is currently completed. The enrollment target is 5,290 participants. The study started on 2011-05. Estimated completion is 2012-09.
Who is sponsoring clinical trial NCT01366027?
This trial is sponsored by Avanir Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.